Bringing a new drug to market involves more than just getting regulatory approval. Pharmaceutical companies must also secure favorable pricing and reimbursement decisions from payers and health technology assessment (HTA) groups. This process bridges the different goals of regulators evaluating safety/efficacy and payers focused on cost-effectiveness.

Key takeaways

  • Regulatory approval does not guarantee payer acceptance and reimbursement.
  • HTA requirements vary across countries despite harmonization efforts.
  • Providing evidence of improved real-world benefits over current treatments.
  • Dealing with uncertainties around using surrogate endpoints accepted by regulators.
  • Timing of HTA submissions for fastest patient access after approval

Thorough preparation is important for navigating this complex landscape. Read this whitepaper to understand how to build a compelling value case, generate relevant data, and effectively negotiate pricing and reimbursement.

Authors

Steffen Thirstrup

Carole Longson

LET’S TALK

You don't have to go it alone!

Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs

This field is for validation purposes and should be left unchanged.